259 related articles for article (PubMed ID: 18354138)
1. Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
Grefhorst A; McNutt MC; Lagace TA; Horton JD
J Lipid Res; 2008 Jun; 49(6):1303-11. PubMed ID: 18354138
[TBL] [Abstract][Full Text] [Related]
2. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
3. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.
Lagace TA; Curtis DE; Garuti R; McNutt MC; Park SW; Prather HB; Anderson NN; Ho YK; Hammer RE; Horton JD
J Clin Invest; 2006 Nov; 116(11):2995-3005. PubMed ID: 17080197
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
5. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
6. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
8. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.
Luo Y; Warren L; Xia D; Jensen H; Sand T; Petras S; Qin W; Miller KS; Hawkins J
J Lipid Res; 2009 Aug; 50(8):1581-8. PubMed ID: 19060325
[TBL] [Abstract][Full Text] [Related]
9. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia.
Pandit S; Wisniewski D; Santoro JC; Ha S; Ramakrishnan V; Cubbon RM; Cummings RT; Wright SD; Sparrow CP; Sitlani A; Fisher TS
J Lipid Res; 2008 Jun; 49(6):1333-43. PubMed ID: 18354137
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for LDL receptor recognition by PCSK9.
Kwon HJ; Lagace TA; McNutt MC; Horton JD; Deisenhofer J
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):1820-5. PubMed ID: 18250299
[TBL] [Abstract][Full Text] [Related]
12. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
13. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.
McNutt MC; Lagace TA; Horton JD
J Biol Chem; 2007 Jul; 282(29):20799-803. PubMed ID: 17537735
[TBL] [Abstract][Full Text] [Related]
14. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.
Seidah NG; Poirier S; Denis M; Parker R; Miao B; Mapelli C; Prat A; Wassef H; Davignon J; Hajjar KA; Mayer G
PLoS One; 2012; 7(7):e41865. PubMed ID: 22848640
[TBL] [Abstract][Full Text] [Related]
15. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.
Ni YG; Di Marco S; Condra JH; Peterson LB; Wang W; Wang F; Pandit S; Hammond HA; Rosa R; Cummings RT; Wood DD; Liu X; Bottomley MJ; Shen X; Cubbon RM; Wang SP; Johns DG; Volpari C; Hamuro L; Chin J; Huang L; Zhao JZ; Vitelli S; Haytko P; Wisniewski D; Mitnaul LJ; Sparrow CP; Hubbard B; Carfí A; Sitlani A
J Lipid Res; 2011 Jan; 52(1):78-86. PubMed ID: 20959675
[TBL] [Abstract][Full Text] [Related]
16. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Roubtsova A; Munkonda MN; Awan Z; Marcinkiewicz J; Chamberland A; Lazure C; Cianflone K; Seidah NG; Prat A
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):785-91. PubMed ID: 21273557
[TBL] [Abstract][Full Text] [Related]
17. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.
Nguyen MA; Kosenko T; Lagace TA
J Lipid Res; 2014 Feb; 55(2):266-75. PubMed ID: 24296664
[TBL] [Abstract][Full Text] [Related]
18. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
20. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
Zhang DW; Lagace TA; Garuti R; Zhao Z; McDonald M; Horton JD; Cohen JC; Hobbs HH
J Biol Chem; 2007 Jun; 282(25):18602-18612. PubMed ID: 17452316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
